In probing B-cell tumor origins, immunogenetic variable (V) region gene analysis has proved to be an incisive tool. One feature revealed by this analysis is the impact of somatic mutation in V genes, which in normal B-cells is generally confined to germinal centers (GCs) in lymphoid organs. 1 Isotype class switch by deletional DNA recombination (CSR) can also occur here, and can be tracked by IgH locus gene probes. CSR is preceded by induction of sterile germline switch transcripts (GTs), with excision of looped out switch circle DNA transcribed to generate circle transcripts (CTs). 1 However, both mutation and isotype switch are by no means restricted to GC sites, and can occur ectopically. For both mutation and CSR mechanisms, the enzyme activation induced cytidine deaminase (AID) is a critical pre-requisite. 1 An important feature is that most normal human B-cells exiting the GC express and retain CD27 in the periphery. 2 Waldenstrom's macroglobulinemia (WM) is a distinct clinicopathological entity with an underlying monoclonal IgM lymphoplasmacytic lymphoma. It locates primarily in the bone marrow (BM) as a tumor of mature sIgM þ ve B-cells, some maturing to secrete immunoglobulin. In WM, V H gene analysis had suggested tumor origins from a post-follicular B-cell which arrests before isotype switch. 3 Some WM cases though have now been identified with germline V H genes, indicative of pre-GC naive B-cell origins, but the extent of heterogeneity in disease origins remains unknown. 4 Moreover, it has been recently suggested that CSR may be impaired in WM in vivo, 5 appearing to substantiate pre-switch arrest in this tumor. To probe disease presentation further, we have re-evaluated these findings, investigating in particular the in vivo isotype switch potential in WM by increasing assay sensitivity.
In this study, BM mononuclear cells (MNCs) were analyzed from IgM-expressing WM (M-WM) presentation cases. Two cohorts were examined. In one, cDNA was isolated from purified tumor cells and amplified (amp-cDNA) for Affymetrix microarray gene expression analysis (unpublished data). In the other, cDNA was not amplified and prepared for V H gene, isotype switch, and AID analysis as reported. 6 The tumor burden as assessed by infiltration of the BM ranged from 10 to 50% in the amp-cDNA cases, and from 32 to 93 (5/9455)% in the nonamplified cDNA cohort. Single cell analysis in M-WM sorted by CD27 expression into single cell tubes was carried out as described. 6 All M-WM cases (16/16) displayed somatically mutated V(D)JCm genes (Table 1 ; data not shown). Employing V H gene-specific probes, mature switched transcripts were surprisingly identified in 7/7 M-WM cases, using amp-cDNA to increase sensitivity. These revealed V(D)J-Ca transcripts in 6/7 cases, co-expressed with Cd (one case), Cd/g (three cases), Cg (two cases), and Cd (one case) ( Table 1) . Switched transcripts were only identified by nestedFpolymerase chain reaction (PCR), indicating a low frequency. The detection of sterile GTs paralleled CT expression (Ia-Ca þ Ia-Cm 1/7; Ig-Cg þ Ig-Cm 7/7), confirming a low level of on-going switch activity (Table 1) . CT expression from switch circle DNA is the hallmark of CSR, and has not been observed in normal circulating B-cells and in tonsillar naive and memory B-cells using comparable RT-PCR based assays, 7 suggesting a tumor-associated feature. AID transcripts were also observed in all cases, functionally intact by sequence (Table 1) , with no variant transcripts identified. These data indicate that initiation of switch events progresses to deletional CSR in WM in vivo. Clearly, these tumors are not inherently defective or totally blocked from undergoing switch activity in vivo.
To pursue the incidence of switch events in M-WM further, additional cases were analyzed where cDNA had not been amplified. In 3/9 of these cases, mature switched transcripts of tumor origin were identifiable at the bulk population level by nested RT-PCR (data not shown), in which Ca-derived transcripts were found alone (2 cases) or co-expressed with Cg (1 case). Of these three cases, one was unsymptomatic and another symptomatic, whereas in the remaining case, further clinical details were not available to assess disease progression.
Comparable assays had previously failed to detect isotype switch in vivo, most likely reflecting limitations of small cohort analysis, [3] [4] [5] although in a few cases, switching could be induced by in vitro maturation stimuli. 5 Availability of material in our M-WM cases allowed further subclonal analysis. Variability in CD27 expression has been suggested in WM, with many tumor-derived cells lacking CD27 despite mutated V H genes. 4 This has been proposed as indicative of origins from an unusual B-cell of origin that has by-passed the GC. 4 To investigate this, V(D)J-Cm transcripts were analyzed in CD27 þ ve and CD27 Àve cells. In 2/2 M-WM cases, tumor-derived V(D)J-Cm transcripts were identifiable in both CD27 þ ve and CD27 Àve single cells ( Figure 1 ). This intratumoral variation in CD27 expression, however, may reflect a diseaseassociated feature. It is conceivable that mutated M-WM derive from CD27
þ ve post-GC B-cells, and that loss of CD27 in clonal cells occurs during disease progression. This has been observed in multiple myeloma (MM), a tumor derived from a mutated post-follicular cell. 8 Here, subclonal loss of CD27 by malignant Transcript identity was confirmed by sequence analysis, in which intact potentially functional sequences were identified. Letters to the Editor plasma cells is associated with advancing disease, and importantly, is predictive of a significantly worse survival outcome, possibly because CD27 loss-variant cells in MM may be escaping apoptosis induced by CD27-CD70 interactions. 8 If mutated WM derives from an unusual B-cell that does not traffic through the GC, 4 WM tumor cells must then acquire CD27 expression in situ, and potentially risk exposure to the CD27-CD70 arm of apoptosis. Clearly, factors that govern modulation of CD27 in WM require further investigation.
C-WM1 CD27-ve single cells
Switch events were also analyzed in CD27 þ /Àve cells to assess tumor-associated features further. In one M-WM case analyzed, variant transcripts could be tracked in both CD27 þ /Àve single cells (Figure 2 ), and were apparent at a low frequency (3/45 overall). Notably, of 42/42 V(D)J-Cm expressing cells analyzed, none was found to co-express switched transcripts, and the few switched cells identified lacked tumorderived Cm transcripts, reinforcing the view that deletional CSR occurs. In some single cells, AID transcripts were also identified albeit at a low frequency, in 2/39 pre-and post-switched cells (Figures 1 and 2) . Observations in single cells confirmed a lowlevel-switch activity in M-WM cells. The underlying mechanisms restricting such differentiation in M-WM, if any, are as yet not defined.
Previous data had suggested that mutated tumor V H sequences are homogeneous when analyzed at the bulk population level, [3] [4] [5] as also found in most of the cases analyzed here (Table 1) . However, one case in the present study revealed a low-level of intraclonal variation, at this level, in tumor V(D)JCm sequences (Table 1 ). This variability was explored further in the two cases examined at single cell level.
V(D)J-Cm sequences in single CD27
þ /Àve tumor-derived cells revealed notable evidence for intraclonal variation in multiple cells in 2/2 cases (Figure 1) . Strikingly, this low-level of on-going events in WM suggests that the BM can support localized mutational activity, with AID expressed. These observations may have further implications. Given that sIg is required for somatic mutation and that this involves a blast phase, 1 it raises the question of what role these tumor cells in M-WM engaged in mutational activity may have in propagating tumor expansion. The extent of variation observed at the single cell level is more extensive and in marked contrast to a very narrow intratumoral variation in V H sequences reported in a single WM case study, which had been analyzed at a whole population level. 9 In that study, only two variant sequences were seen in the monoclonal tumor at that level of analysis. The present study suggests that clonal mutational variants observed here could expand significantly in some cases, and clone out minor variants or to homogeneity. Our observations also suggest that a low level of on-going mutational activity may be a more widespread feature in M-WM, revealing divergence in biological behaviour among tumor cells.
On-going localized mutational events in the BM have also been observed in MGUS, a pre-malignant plasma cell tumor, where heterogeneous tumor-derived V H sequences are identifiable as pre-and post-switched transcripts. 10 With sIg a critical requirement to initiate mutations, this suggests that on-going mutations are occurring in-situ in a less differentiated cell of origin in MGUS, with tumor progeny then maturing terminally. As in MGUS, some WM cells clearly differentiate terminally following mutational activity, indicating that the BM mileau is conducive to localized tumor maturation. Plausibly, the cell of origin for the predominant mutated subset in WM may be derived from normal IgM þ ve post-GC memory B-cells that home to the BM to reside there, retaining the capacity to mature and secrete IgM. A 35-year-old female patient with Noonan Syndrome (NS) presented with leukocytosis and splenomegaly. Aged 13, she had undergone surgery for severe pulmonary valve stenosis with right-to-left atrial shunt. Recent medical history included malaise, lack of appetite and moderately painful, tender red nodules with central ulceration on face, neck and arms. Skin biopsy showed marked oedema and superficial and deep derma granulocyte infiltration, with some eosinophils. Blood counts were: white blood cells, 386 Â 10 9 /l (neutrophils 55%, lymphocytes 7%, monocytes 34%, eosinophils 4%); haemoglobin: 13.5 g/dl; platelets, 336 Â 10 9 /l. Chronic myelomonocytic leukaemia (CMML) was diagnosed on bone marrow aspirate. Karyotype, described according to the International System for Human Cytogenetic Nomenclature, 1995, was 46,XX, t(5;16)(q33;p13)[11]/46,XX [4] (Figure 1a) .
In all cells bearing t(5;16)(q33;p13), fluorescent in situ hybridization (FISH) indicated PDGFRB was rearranged (Figure 1b) . Investigations on the 16p13 breakpoint revealed that DNA clones for 3 0 CBP (cosmids RT191/RT203), 5 0 CBP (cosmids RT166/RT53), NDE1 (CTD-2303E13) and 3 0 MYH11 (cosmids ZIT27/ZIT29) were translocated to der(5). The 5 0 MYH11 (cosmids ZIT14/ZIT18 and clone RP11-844E20) and the entire MRP gene (clone RP11-8H13) were deleted (Figure 1c  and d) . FISH investigation into anthracycline resistance-associated (ARA) gene, as the next centromeric candidate, gave disappointing results. Experiments with clones RP11-517A5, RP11-958N24, RP11-148M17 had to be discarded upon closer sequence analysis (BLAST algorithm, at www.ncbi.nlm.nih.gov/ BLAST) which revealed duplicated or triplicated DNA inserts in the 16p13 region centromeric to NDE1 and MYH11. Consequently, spurious signals could have masked deletion of each probe's target region. DNA clones more centromeric to RP11-148M17 (from RP11-14N3 to RP11-696K16) were retained on der(16) (Figure 1c) . Therefore, the 3 0 MYH11 and the NDE1 gene set the telomeric boundary of the 16p deletion, whereas the 700 kb multiple-copy region included the ARA gene and the undefined centromeric boundary.
As FISH at the 5q33 breakpoint showed a PDGFRB rearrangement, imatinib mesylate was started. After six months, the patient achieved hematological and FISH remission and skin lesions disappeared, confirming findings in another patient with myeloproliferative disorder, cutaneous involvement and t(5;12)(q33;q13) with rearranged PDGFRB. Platelet derived growth factor receptor beta (PDGFRb) tyrosine kinase is expressed in hematopoietic cells, fibroblasts, endothelial cells and osteoblasts and plays a pre-eminent role in monocytic differentiation, vascular repair, tissue inflammation and wound healing. PDGFRB/5q33 balanced translocations identify a subgroup of CMML and atypical chronic myeloid leukaemia presenting, predominantly in males, with bone marrow and/or peripheral blood eosinophilia and splenomegaly. As a result of this translocation, the 3 0 region of PDGFRB encoding the kinase domain fuses with the 5 0 region of a partner gene encoding an oligomerization domain, thus consti-
